Roche's bispecific-ADC combo keeps lymphoma at bay
By Angus Liu
Hematologists Highlight Notable Insights From the 2025 EHA Congress
By Ashling Wahner
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
Roche's Hemophilia Drug Shows Hemostatic Normalization Potential in Early-stage Study
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
Full Coverage of this storyRoche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3
By Lei Lei Wu
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Roche (LON:0QOK) Advances NXT007 in FTSE with Positive Haemophilia Data
First clinical data for Roche's hoped Hemlibra successor impresses
Roche unveils promising Phase 1/2 results for NXT007 in haemophilia A
Full Coverage of this storyRoche, AbbVie's Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
By Tristan Cesar Manalac
Roche provides an update on tominersen: What's next for this huntingtin-lowering drug? – HDBuzz
By Rachel J. Harding
Roche’s high-dose Ocrevus fails primary endpoint in MS trial
By Joshua Silverwood
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
By Paul Arnold & Maggie Fick
Biotech Giant Roche Launches Innovation Center on Harvard's Allston Research Campus | News
By Stephanie Dragoi
Roche Announces SBX Technology, Creates Sequencing Buzz
By Julianna LeMieux
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
By Dan Samorodnitsky
Spotlight On: Roche's Q4 earnings call — Key quotes and what they mean for the company and its competitors
By Simon King
Roche's new deals head tries to navigate a more 'complicated' and 'expensive' biotech world
By Jacob Bell
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
By Tristan Cesar Manalac
Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida
By Rachel More & John Revill
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
By Annalee Armstrong
Roche Confirms Profit Forecast as Sales Beat Estimates
By Helena Smolak
AbbVie to buy Roche spinout for $200 million
By Rowan Walrath
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
By Tristan Cesar Manalac